Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of D-Phenylalanine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 2/20 | 0.96 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.57 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.56 |
| ▸ | LCK known ✓ | P06239 | 1/20 | 0.56 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.56 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.56 |
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.96 |
| ▸ | ALPI | P09923 | 1/20 | 0.96 |
| ▸ | PKM | P14618 | 1/20 | 0.96 |
| ▸ | XIAP | P98170 | 1/20 | 0.96 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.67 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.67 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.67 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.58 |
| ▸ | LTA4H | P09960 | 1/20 | 0.58 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dl-Phenylalanine SCHEMBL245923 | 1.00 | SLC7A5 (0.96) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL27938150 | 1.00 | SLC7A5 (0.96) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL245924 | 1.00 | SLC7A5 (0.96) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL9318219 | 1.00 | SLC7A5 (0.96) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL10425092 | 1.00 | SLC7A5 (0.96) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL16893995 | 1.00 | SLC7A5 (0.96) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL10425093 | 1.00 | SLC7A5 (0.96) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL16893993 | 1.00 | SLC7A5 (0.96) | SLC7A5PTGS1ALPIPKMXIAP | |
| D-Phenylalanine SCHEMBL21410545 | 1.00 | SLC7A5 (0.96) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL9318215 | 1.00 | SLC7A5 (0.96) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102432413-B | Purification method for improving chiral purity of D-amino acid | UNIV CHONGQING POSTS & TELECOM | 2014-02-19 | — | — | CN | claimed |
| WO-2022265577-A2 | CORONAVIRUS ENZYME MODULATORS, METHODS OF SYNTHESIS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-12-22 | — | — | WO | disclosed |
| EP-3596052-B1 | CHEMICAL COMPOUNDS | NODTHERA LTD (GB) | 2022-07-20 | — | — | EP | disclosed |
| US-11345669-B2 | Urea derivatives and methods of use thereof | NodThera Limited (GB) | 2022-05-31 | — | — | US | disclosed |
| US-20200131141-A1 | CHEMICAL COMPOUNDS | NodThera Limited (GB) | 2020-04-30 | — | — | US | disclosed |
| WO-2018167468-A1 | CHEMICAL COMPOUNDS | NodThera Limited (GB) | 2018-09-20 | — | — | WO | disclosed |
| EP-2755985-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS LLC (US) | 2017-11-01 | — | — | EP | disclosed |
| CN-105793237-A | Benzamide derivatives for the treatment of muscular disorders and pain and for the control of spasticity and tremors | 坎贝克斯治疗有限公司 | 2016-07-20 | — | — | CN | disclosed |
| US-8951985-B2 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| CN-102432413-B | Purification method for improving chiral purity of D-amino acid | UNIV CHONGQING POSTS & TELECOM | 2014-02-19 | — | — | CN | disclosed |
| EP-0515548-A4 | IMIDAZOLE ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | — | 1993-03-10 | — | — | EP | disclosed |
| EP-0527534-A1 | Quinoline and azaquinoline angiotensin II antagonists | MERCK & CO. INC. (US) | 1993-02-17 | — | — | EP | disclosed |
| US-5183810-A | Hyptoensive agents | MERCK & CO., INC. (US) | 1993-02-02 | — | — | US | disclosed |
| EP-0515548-A1 | IMIDAZOLE ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | MERCK & CO. INC. (US) | 1992-12-02 | — | — | EP | disclosed |
| WO-1991012002-A1 | IMIDAZOLE ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | MERCK & CO., INC. (US) | 1991-08-22 | — | — | WO | disclosed |
| US-4766250-A | Racemization catalyst for amino acids | STAUFFER CHEMICAL CO. (US) | 1988-08-23 | — | — | US | disclosed |
| US-4713470-A | Racemization of amino acids | STAUFFER CHEMICAL COMPANY (US) | 1987-12-15 | — | — | US | disclosed |
| US-4642205-A | Diastereomer salts of phenylalanine and N-acyl derivatives thereof and process for the separation of optically active phenylalanine and N-acyl derivatives thereof | ALKALOIDA VEGYESZETI GYAR (HU) | 1987-02-10 | — | — | US | disclosed |
| EP-0174358-A1 | NOVEL DIASTEREOMER SALTS OF PHENYLALANINE AND N-ACYL DERIVATIVES THEREOF AND PROCESS FOR THE SEPARATION OF OPTICALLY ACTIVE PHENYLALANINE AND N-ACYL DERIVATIVES THEREOF | ALKALOIDA VEGYéSZETI GYáR (HU) | 1986-03-19 | — | — | EP | disclosed |
| WO-1985003932-A1 | NOVEL DIASTEREOMER SALTS OF PHENYLALANINE AND N-ACYL DERIVATIVES THEREOF AND PROCESS FOR THE SEPARATION OF OPTICALLY ACTIVE PHENYLALANINE AND N-ACYL DERIVATIVES THEREOF | ALKALOIDA VEGYÉSZETI GYÁR (HU) | 1985-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131141-A1 | CHEMICAL COMPOUNDS | IL1B, CASP1, IL1A | PTGS1 80/4885HDAC8 1230/4885EGFR 4584/4885 |
| US-11345669-B2 | Urea derivatives and methods of use thereof | IL1B, IL1A, NOD1 | PTGS1 208/4885HDAC8 2195/4885EGFR 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.